Posts

Posted on

ACI Worldwide and BigDataCorp Deliver Safer Access to eCommerce in Brazil Through Increased Fraud Detection Accuracy

ACI Worldwide and BigDataCorp Deliver Safer Access to eCommerce in Brazil Through Increased Fraud Detection Accuracy

  • CPF identity verification service helps merchants identify genuine customers, adds extra layer of validation to keep fraudsters at bay
  • Joint solution increases fraud detection accuracy and boosts acceptance rates
  • Merchants benefit from operational efficiencies and reduced fraud and chargebacks

MIAMI–(BUSINESS WIRE)–ACI Worldwide (NASDAQ: ACIW), a leading global provider of real-time digital payment software and solutions, today announced that it has partnered with BigDataCorp, a leading Latin American data specialist, to provide eCommerce merchants operating in Brazil with a CPF (Cadastro de Pessoas Físicas or Natural Persons Register) identity verification service, which adds an extra layer of validation for genuine customers. With this service, merchants in Brazil can ensure only legitimate orders are approved.

The CPF number, assigned to individuals by the Brazilian revenue agency, is a taxpayer registry identification number, which merchants can use to validate a purchase by checking if a customer is in good standing. With the ACI Secure eCommerce and BigDataCorp solutions, merchants can send and cross-reference specific CPF data for validation, allowing them to safely transact with Brazilian customers and easily detect any fraudulent activity. The BigDataCorp solution works seamlessly with ACI Secure eCommerce to increase fraud detection accuracy without the need for technical integration.

“Fraud is prevalent in Brazil and chargebacks are commonplace. In addition, poor transactional data quality and availability can make fraud detection a challenge. The CPF card is essential to enabling a successful checkout experience,” said Thoran Rodrigues, CEO, BigDataCorp. “The addition of the CPF card validation in an order provides merchants with a higher level of confidence around the authenticity of a purchase and helps them contain costs by reducing fraud and chargebacks. Our partnership with ACI is important for merchants looking to expand their business in Brazil.”

With the ACI and BigDataCorp partnership, required data is submitted to the third party on behalf of merchants. A real-time callout, data and communication exchange improves fraud detection accuracy and delivers enhanced control of the fraud and customer management processes. Merchants can increase operational efficiencies by reducing manual review volumes, which results in not only cost savings, but also market growth.

“While Brazil has seen a significant boost in eCommerce over the last year, fraud has also run rampant. With mobile commerce expected to reach $20 billion by 2023, merchants and their customers need extra protection,” said Debbie Guerra, executive vice president, ACI Worldwide. “By partnering with BigDataCorp, we are enabling our customers and prospects to safely do business in a key emerging market, with an increasingly mobile-first population.”

About ACI Worldwide

ACI Worldwide is a global software company that provides mission-critical real-time payment solutions to corporations. Customers use our proven, scalable and secure solutions to process and manage digital payments, enable omni-commerce payments, present and process bill payments, and manage fraud and risk. We combine our global footprint with local presence to drive the real-time digital transformation of payments and commerce.

© Copyright ACI Worldwide, Inc. 2021

ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties’ trademarks referenced are the property of their respective owners.

Media Contacts

Dan Ring

[email protected]

781-370-3600

Nidhi Alberti

[email protected]

781-370-3600

KEYWORDS: Florida United States South America North America Brazil

INDUSTRY KEYWORDS: Technology Finance Security Banking Professional Services Software Retail Data Management Online Retail

MEDIA:

Logo
Logo
Posted on

Alpha and Omega Semiconductor Announces Application-Specific EZBuck™ Regulator to Power Intel Rocket Lake Platform

Alpha and Omega Semiconductor Announces Application-Specific EZBuck™ Regulator to Power Intel Rocket Lake Platform

AOZ2263VQI-01 and AOZ2263VQI-02 with Adjustable Output Voltage using 2-bit VID Provides Highest Power Density Solution for Intel Rocket Lake CPU VCCIO Rails

SUNNYVALE, Calif.–(BUSINESS WIRE)–Alpha and Omega Semiconductor Limited (AOS) (Nasdaq: AOSL), a designer, developer, and global supplier of a broad range of power semiconductors, power ICs, and digital power products, today introduced a new family of application-specific EZBuck™ regulators. The AOZ2263VQI-01 and AOZ2263VQI-02 are offered in a QFN 4 x 4 package and offer the industry’s most compact footprint to support VCCIO rails in Intel Rocket Lake platforms used in desktop computing systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005089/en/

AOZ2263VQI-01 and AOZ2263VQI-02 with Adjustable Output Voltage using 2-bit VID Provides Highest Power Density Solution for Intel Rocket Lake CPU VCCIO Rails (Graphic: Business Wire)

AOZ2263VQI-01 and AOZ2263VQI-02 with Adjustable Output Voltage using 2-bit VID Provides Highest Power Density Solution for Intel Rocket Lake CPU VCCIO Rails (Graphic: Business Wire)

Intel’s Rocket Lake platform consists of two VCCIO rails; VCCIO_0 and VCCIO_1_2 power multiple I/O in Intel CPU. High-performance, personal computing systems support add-on features requiring high-speed input/output communication. These feature-rich personal computing systems require VCCIO rails with high currents and typical competitor power implementations require either a controller with external discrete power FETs or a converter with a large package. In contrast, AOS’s highly integrated solution includes all the power silicon in a single QFN 4 x 4 package for 12A.

Technical Highlights

The AOZ2263VQI-01 and AOZ2263VQI-02 converters include features specifically designed to meet the Intel Rocket Lake Platform’s specifications. The 2-bit VID pins allow the VCCIO_0 and VCCIO_1_2 power rail to adjust with voltage for 1.05V, 1.075V, 1.1V, 1.125V, and 0.8V, 0.95, 1.0V, 1.05V, respectively, depending on multiple systems operating modes. Both devices have also passed all the validation requirements included in the Intel Rocket Lake Platform component list. This validation puts the regulator through stringent tests to ensure compliance with Intel specifications. AOS’s proprietary COT architecture provides ultra-fast load transient response performance and enables stable and low voltage ripple operation with small-sized ceramic capacitors, further reducing solution size and cost. AOS EZBuck family is highly integrated; featuring a PGOOD output, an integrated bootstrap diode and integrated soft start. Protection features include cycle-by-cycle current limit, short-circuit protection (SCP), Overvoltage Protection (OVP) and Thermal shutdown. A Low Power Mode (LPM) pin also allows system designs to lower VCCIO rails down to 0V for minimizing system power consumption in standby or idle mode.

Key Features

  • Supports Intel Rocket Lake Platform 2 bits VID and Low Power Mode (LPM)
  • AOZ2263VQI-01, VID Range = 1.05V to 1.125V
  • AOZ2263VQI-02, VID Range = 0.8V to 1.05V
  • Wide input voltage range: 4V to 28V
  • High Current Capability: 12A
  • Low RDS(ON) internal NFETs: 11mOhm HS FET, 7mOhm LS FET
  • Thermally enhanced 4 x 4 QFN package

“The current capability offered by the AOZ2263VQI-01 and the AOZ2263VQI-02 offers designers an easy-to-use solution to support Intel Rocket Lake’s platform. In today’s ever shrinking desktop motherboard form factors, PCB real estate is at a premium. Utilizing AOS’s EZBuck regulator platform technology enables AOS to solve the system designer’s problem of ever-shrinking PCB real estate,” said Wayne Lee, Power IC Marketing at AOS.

Pricing and Availability

The AOZ2263VQI-01 and the AOZ2263VQI-02 are immediately available in production quantities with a lead-time of 12 weeks. The unit price for 1,000 pieces is $1.058 for the AOZ2263VQI-01 and the AOZ2263VQI-02.

About AOS

Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer, and global supplier of a broad range of power semiconductors, including a wide portfolio of Power MOSFET, IGBT, IPM, TVS, HVIC, SiC/GaN, Power IC, and Digital Power products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables us to introduce innovative products to address the increasingly complex power requirements of advanced electronics. AOS differentiates itself by integrating its Discrete and IC semiconductor process technology, product design, and advanced packaging know-how to develop high-performance power management solutions. AOS’s portfolio of products targets high-volume applications, including portable computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls, automotive electronics, and power supplies for TVs, computers, servers, and telecommunications equipment. For more information, please visit www.aosmd.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts, and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, references to the efficiency and capability of new products and the potential to expand into new markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the actual product performance in volume production, the quality and reliability of the product, our ability to achieve design wins, the general business and economic conditions, the state of the semiconductor industry, and other risks as described in the Company’s annual report and other filings with the U.S. Securities and Exchange Commission. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date unless otherwise stated, and AOS undertakes no duty to update such information, except as required under applicable law.

Media Contact: Mina Galvan

Tel: 408.789.3233

Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Networks Semiconductor Hardware Data Management Technology

MEDIA:

Photo
Photo
AOZ2263VQI-01 and AOZ2263VQI-02 with Adjustable Output Voltage using 2-bit VID Provides Highest Power Density Solution for Intel Rocket Lake CPU VCCIO Rails (Graphic: Business Wire)
Posted on

ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®

ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®

MARIETTA, Ohio–(BUSINESS WIRE)–
ProtoKinetix, Incorporated (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP®.

For the development of this drug for DED to date the company has completed:

  1. Ocular irritation studies
  2. Proof of concept pre-clinical DED trials for efficacy
  3. Confirmatory pre-clinical DED trials for efficacy
  4. Pilot drug stability (ie. shelf-life) testing
  5. Pilot tolerability and toxicology studies

All these studies were conducted by market-leading contract research organizations (CRO).

In order to progress to clinical trials, the Company intends to complete the following activities:

  1. Complete topical application formulation(s)
  2. Confirmatory DED efficacy tests
  3. Drug product Good Lab Practice (GLP) IND-enabling safety toxicology
  4. Communicate with Federal Drug Administration (FDA) on clinical trial design criteria

Dry Eye Disease Market Overview

According to market research published by Mordor Intelligence LLP, studies of the Dry Eye Disease market indicated a value of approximately USD 4.5 billion in 2018, and the market is expected to reach up to USD 6.2 billion by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019-2024). The growth of dry eye related diseases may include several factors, such as aging, a decrease in the supportive hormones (ex. menopause), systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.

“This is a critical milestone in our application development and moves us forward to commercialization of ProtoKinetix’s Dry Eye Disease program.” – Clarence Smith, CEO President

See the promising research of AAGP® and results to date

Visit our new website at ProtoKinetix.com for more information and to join our email list.

About ProtoKinetix, Incorporated

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.

Clarence E. Smith

President and Chief Executive Officer

Telephone: 740-434-5041

Email: [email protected]

LinkedIn

Twitter: @ProtoKinetix

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Health Stem Cells Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Posted on

Dynatrace to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results

Dynatrace to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results

WALTHAM, Mass.–(BUSINESS WIRE)–
Software intelligence company Dynatrace (NYSE: DT) announced today it will report financial results for the fiscal fourth quarter and full year ended March 31, 2021, before market open on May 12, 2021.

Dynatrace will host a conference call and live webcast to discuss its financial results and business outlook for investors and analysts at 8:00 a.m. Eastern Time on May 12, 2021. To access the conference call from the U.S. and Canada, dial (866) 405-1247, or internationally, dial (201) 689-8045 with conference ID # 13718082. The call will also be available live via webcast on the company’s website, ir.dynatrace.com. An audio replay of the call will also be available until 11:59 p.m. Eastern Time on May 26, 2021, by dialing (877) 660-6853 from the U.S. or Canada, or for international callers by dialing (201) 612-7415 and entering conference ID # 13718082. In addition, an archived webcast will be available at ir.dynatrace.com.

About Dynatrace

Dynatrace provides software intelligence to simplify cloud complexity and accelerate digital transformation. With automatic and intelligent observability at scale, our all-in-one platform delivers precise answers about the performance and security of applications, the underlying infrastructure and the experience of all users to enable organizations to innovate faster, collaborate more efficiently, and deliver more value with dramatically less effort. That’s why many of the world’s largest enterprises trust Dynatrace® to modernize and automate cloud operations, release better software faster, and deliver unrivaled digital experiences.

To learn more about how Dynatrace can help your business, visit www.dynatrace.com, visit our blog and follow us on Twitter @dynatrace.

Investors:

Noelle Faris

VP, Investor Relations

[email protected]

Media Relations:

Jerome Stewart

VP, Communications

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Technology Semiconductor Security Satellite Photography Telecommunications Nanotechnology Software Audio/Video VoIP Networks Internet Mobile/Wireless Hardware Electronic Design Automation Data Management Consumer Electronics

MEDIA:

Logo
Logo
Posted on

Noxopharm Files Septic Shock Treatment Patent for Veyonda®

Noxopharm Files Septic Shock Treatment Patent for Veyonda®

New indication doubles the commercial opportunity

SYDNEY–(BUSINESS WIRE)–
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.

Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock.

Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response to repair damaged tissue such as virally-infected lungs. In some individuals, the STING response is inappropriately excessive, pushing the individual over into septic shock. Veyonda is the first drug that blocks STING to be tested in septic shock, including in COVID-19 patients.

Graham Kelly, CEO of Noxopharm, said, “Globally, someone dies every three seconds from septic shock, the same rate as cancer. A cost-effective treatment for septic shock doubles the commercial opportunity for Veyonda.”

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

Jane Byram

SCORR Marketing

+1 512-626-2758

[email protected]

KEYWORDS: Australia/Oceania Europe Australia Asia Pacific

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Oncology Health Infectious Diseases Clinical Trials

MEDIA:

Logo
Logo
Posted on

NeoPhotonics to Host Conference Call to Discuss 2021 First Quarter Financial Results on Thursday, April 29, 2021

NeoPhotonics to Host Conference Call to Discuss 2021 First Quarter Financial Results on Thursday, April 29, 2021

SAN JOSE, Calif.–(BUSINESS WIRE)–
NeoPhotonics Corporation (NYSE: NPTN), a leading developer of silicon photonics and advanced hybrid photonic integrated circuit-based lasers, modules and subsystems for bandwidth-intensive, high speed communications networks, will report its financial results for the first quarter ended March 31, 2021, after market close on Thursday, April 29, 2021.

The company will host a conference call to discuss these results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, April 29, 2021. Chief Executive Officer, Tim Jenks and Chief Financial Officer, Beth Eby will provide an overview of the results, discuss current business conditions and conduct a question-and-answer session.

The call will be available, live, to interested parties by dialing 800-367-2403 or +1 334-777-6978. The Conference ID number is 4824979. Please dial into the conference call 5-10 minutes prior to the scheduled start time.

A live webcast will be available in the Investor Relations section of NeoPhotonics’ website at: http://ir.neophotonics.com/phoenix.zhtml?c=236218&p=irol-calendar.

A replay of the webcast will be available in the Investor Relations section of the company’s web site approximately two hours after the conclusion of the call and remain available for approximately 30 calendar days.

About NeoPhotonics

NeoPhotonics is a leading developer and manufacturer of lasers and optoelectronic solutions that transmit, receive and switch high-speed digital optical signals for Cloud and hyper-scale data center internet content provider and telecom networks. The Company’s products enable cost-effective, high-speed over distance data transmission and efficient allocation of bandwidth in optical networks. NeoPhotonics maintains headquarters in San Jose, California and ISO 9001:2015 certified engineering and manufacturing facilities in Silicon Valley (USA), Japan and China. For additional information visit www.neophotonics.com.

©2021 NeoPhotonics Corporation. All rights reserved. NeoPhotonics and the red dot logo are trademarks of NeoPhotonics Corporation. All other marks are the property of their respective owners.

NeoPhotonics Corporation

Beth Eby, Chief Financial Officer

+1-408-895-6086

[email protected]

Sapphire Investor Relations, LLC

Erica Mannion, Investor Relations

+1-617-542-6180

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Semiconductor Engineering Telecommunications Manufacturing Software Internet Hardware Data Management

MEDIA:

Posted on

Kopin To Participate in New Webinar Series – AR and VR: The Paradigm Shift to Smartglasses Starts Now

Kopin To Participate in New Webinar Series – AR and VR: The Paradigm Shift to Smartglasses Starts Now

WESTBOROUGH, Mass.–(BUSINESS WIRE)–
Kopin® Corporation (NASDAQ: KOPN), a leading developer and provider of transmissive and reflective active matrix liquid crystal and organic light emitting diode (OLED) microdisplays used in military, enterprise, industrial, medical and consumer products, announced that its CEO, Dr. John Fan, will participate in a new three-part webinar series “AR and VR: The Paradigm Shift to Smartglasses Starts Now”.

  • Part 1: AR and VR: The Paradigm Shift to Smartglasses Starts Now – The Past

    Presentation: Tuesday, April 27, 2021 at 12:00pm ET.

    Click Here to Register
  • Part 2: AR and VR: The Paradigm Shift to Smartglasses Starts Now – The Past

    Presentation: Wednesday, May 12, 2021 at 12:00 pm ET

    Click Here to Register
  • Part 3: AR and VR: The Paradigm Shift to Smartglasses Starts Now – The Past

    Presentation: Wednesday, May 26, 2021 at 12:00 pm ET

    Click Here to Register

In part one, Dr. Fan will talk about past efforts to create AR/VR solutions and some of the lessons learned from some of these high-profile efforts. In part two, he will tackle the present state of the art, profiling some interesting successes, and pronouncing that the tipping point has arrived in some markets. In part three, Dr. Fan will look to the future of AR/VR smart glasses, offering a roadmap to successful product development needed for eventual platform shift. In ten to fifteen years, it can grow to a trillion-dollar market.

Dr. Fan is uniquely qualified to present his vision of the AR/VR journey having worked to develop AR and VR solutions for 30 years, starting with Kopin’s pioneering work for DARPA on microdisplays and systems.

“Kopin has been an innovator in the AR/VR space for a long time and I have seen many successes and failures,” noted Dr. Fan. “So many elements must come together to offer a compelling AR or VR solution and we technologists can get too impatient or too aggressive in making the big leap. Or, we get lost in the lab working on individual separate pieces and lose track of the bigger picture. This webinar series is designed to take a step back from the technical details and look at AR and VR in a broader, more holistic, historical and aspirational perspective,” concluded Dr. Fan.

About Kopin

Kopin Corporation is a leading developer and provider of innovative display and optical technologies sold as critical components and subassemblies for military, industrial and consumer products. Kopin’s technology portfolio includes ultra-small Active Matrix Liquid Crystal displays (AMLCD), Liquid Crystal on Silicon (LCOS) displays and Organic Light Emitting Diode (OLED) displays, a variety of optics, and low-power ASICs. For more information, please visit Kopin’s website at www.kopin.com.

Kopin

Richard Sneider, 508-870-5959

Treasurer and Chief Financial Officer

[email protected]

or

Market Street Partners

Joann Horne, 415-445-3233

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Engineering Health Technology Manufacturing Audio/Video Optical Hardware

MEDIA:

Posted on

Temas Resources and Erin Ventures Ready Agreement for the Joint Development of Piskanja Boron Project

Temas Resources and Erin Ventures Ready Agreement for the Joint Development of Piskanja Boron Project

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Temas Resources Corp. (CSE: TMAS, OTCQB: TMASF, FSE: 26P) (the “Company” or “Temas Resources”), is pleased to announce that, further to its news release dated December 18, 2020 in which Temas Resource stated that it had entered into a Letter of Intent (“LOI”) with Erin Ventures Inc. (“Erin Ventures”) for the joint development of Erin Ventures’ Piskanja Borate Project. The parties have recently concluded their due diligence process with a favourable outcome. Temas Resources and Erin Ventures are now working to complete a definitive binding agreement based on the terms in the LOI. It is anticipated that the definitive agreement will be completed imminently.

Piskanja is Erin Ventures’ wholly owned boron deposit with an indicated mineral resource of 7.8 million tonnes (averaging 31.0% B2O3), and an inferred resource of 3.4 million tonnes (averaging 28.6% B2O3). Calculated in accordance with the Canadian Institute of Mining Definition Standards on Mineral Resources and Reserves (“CIM Standards”) as disclosed in Erin Ventures’ report titled “Mineral Resource Estimate Update on the Piskanja Borate Project, Serbia, October 2016 – Amended February 28 2019” prepared by SRK Consulting (UK) Ltd. The responsible persons for the Updated Mineral Resource Estimate are Dr. Mike Armitage (C.Eng., C.Geol.) and Dr. Mikhail Tsypukov, both of whom arefull-time employees of SRK and Qualified Persons in accordance with CIM Standards and independent of Erin Ventures.

About Temas Resources

Temas Resources Corp. (“Temas Resources”) (CSE:TMAS) (OTCQB:TMASF) (FSE: 26P) is focused on the advancement of mineral independence and the processes in which minerals are extracted in an environmentally friendly manner. Temas Resources invests in and works to apply green technology across its mining portfolio to reduce the environmental impact and carbon footprint of metal extraction through advanced processing and patented leaching technologies.

Temas Resources flagship properties are located in the stable, mining-friendly jurisdiction of Quebec (Canada) bordering Vermont, Maine, and New York State (U.S.) in an area known as the Grenville Geological Province. The Grenville Geological Province is home to Lac Tio, the largest solid ilmenite deposit in the world.

As a mineral exploration company focused on the environmentally friendly acquisition, exploration and development of Iron, Titanium, and Vanadium properties in a socially responsible manner, Temas Resources has focused its efforts on advancing two major projects in the Grenville Geological Province area. The first, the DAB Property, is an option for 100% interest consisting of 128 contiguous mineral claims which covers 6,813.72 hectares (68.14 km2) within the Grenville Geological Province. The flagship, the La Blache Property, is 100% ownership of 48 semi-contiguous mineral claims which cover 2,653.25 hectares (26.53 km2) within the Grenville Geological Province. All public filings for the Company can be found on the SEDAR website www.sedar.com. For more information about the Company, please visitwww.temasresources.com.

About Erin Ventures

Erin Ventures Inc. (“Erin Ventures”) is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Erin Ventures’ shares are traded on the TSX Venture Exchange under the symbol “EV”. For detailed information, please see Erin’s website atwww.erinventures.com or the Company’s filed documents at www.sedar.com.

Qualified Person

Rory Kutluoglu, B.Sc, P.Geo, is the Qualified Person as defined by NI 43-101 who has reviewed and approved the technical information contained within this press release.

On behalf of the Board of Directors of Temas Resources Corp.,

“Kyler Hardy”

Director

Forward Looking Statements

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Temas Resources, future growth potential for Temas Resources and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of iron, titanium, vanadium and other metals; no escalation in the severity of the COVID-19 pandemic; costs of exploration and development; the estimated costs of development of exploration projects; Temas Resources’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

These statements reflect Temas Resources’ respective current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by management, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or forward-looking information and Temas Resources has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the Company’s dependence on one mineral project; precious metals price volatility; risks associated with the conduct of the Company’s mining activities in Quebec; regulatory, consent or permitting delays; risks relating to reliance on the Company’s management team and outside contractors; risks regarding mineral resources and reserves; the Company’s inability to obtain insurance to cover all risks, on a commercially reasonable basis or at all; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; contests over title to properties, particularly title to undeveloped properties; laws and regulations governing the environment, health and safety; the ability of the communities in which the Company operates to manage and cope with the implications of COVID-19; the economic and financial implications of COVID-19 to the Company; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; the Company’s interactions with surrounding communities and artisanal miners; the Company’s ability to successfully integrate acquired assets; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; lack of liquidity for shareholders of the Company; litigation risk; and the factors identified under the caption “Risk Factors” in Temas Resources’ management discussion and analysis. Readers are cautioned against attributing undue certainty to forward-looking statements or forward-looking information. Although Temas Resources has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. Temas Resources does not intend, and does not assume any obligation, to update these forward-looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

For further information or investor relations inquiries, please contact us:

Nick Spencer

Investor Relations

[email protected]

www.temasresources.com

or

Dave Burwell

Vice President

The Howard Group Inc.

Email: [email protected]

Tel: 403-410-7907

Toll Free: 1-888-221-0915

For inquiries on using the Temas family of technologies please contact:

Michael Dehn

President and CEO

E-mail: [email protected]

Tel: 647-477-2382

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Posted on

Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities

Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Pure Biologics to accelerate the discovery of immuno-oncology antibody-based drugs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005273/en/

“Twist’s unique technological approaches and abilities allow for the rapid generation of diverse synthetic libraries with novel and recent data-based randomization schemes. Combined with our immuno-oncology pipeline and scientific background in the field of therapeutic bispecific antibodies and antibodies bearing protein fusions, we expect this partnership to accelerate our discovery pipeline and build a base for research expansion in the future,” said Filip Jelen, Ph.D., CEO of Pure Biologics SA.

Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will grant Pure Biologics’ access to select synthetic antibody phage display libraries derived only from sequences that exist in the human body and further optimized by leveraging state-of-the-art approaches, including artificial intelligence and big data analytics. Certain libraries among the portfolio are deliberately tailored to match chosen classes of biological targets as well as to enhance bispecific antibody forming capabilities. Together, the companies will work to discover, validate and optimize new antibody candidates against targets useful for immuno-oncology applications. Pure Biologics will pay Twist annual technology access fees in addition to future payments for preclinical, clinical and commercial achievement for any antibodies resulting from the collaboration.

“We look forward to augmenting Pure Biologics’ immuno-oncology pipeline with first-in-class bispecific antibodies identified and designed using our robust discovery and optimization engine,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Highly selective, potent bispecific antibodies that bind to multiple targets have the potential to change the way cancer is treated in the future.”

About Pure Biologics

Pure Biologics SA (WSE (PL): PUR) is an emerging biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology and rare neurological diseases, conducting research for the selection and development of active molecules – antibodies and aptamers.

About Twist Biopharma

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability for the partnership to accelerate the discovery of immuno-oncology antibody-based drugs, to accelerate Pure Biologic’s discovery pipeline and build a base for research expansion, to validate and optimize new antibody candidates against targets useful for immuno-oncology applications and to augment Pure Biologic’s immuno-oncology pipeline, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on February 9, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Angela Bitting

SVP, Corporate Affairs

925- 202-6211

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients

SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of chronic hepatitis B (CHB) patients in the ongoing ALG-000184-201 study (NCT04536337). The trial is evaluating ALG-000184, a proprietary Class II capsid assembly modulator (CAM) designed to inhibit viral replication, as determined by HBV DNA and RNA levels.

“To fully suppress the hepatitis B virus, we believe you must not only remove the immunosuppressive effects of high S-antigen levels using oligonucleotide drug candidates such as our STOPS™ molecule, ALG-010133, but also inhibit replication of the virus using small molecule drug candidates such as our CAM, ALG-000184,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “We believe combination approaches such as giving ALG-010133 and ALG-000184 together with a nucleos(t)ide analog therapy have the potential to achieve higher rates of functional cure than with current standard of care.”

Matthew W. McClure, M.D., Chief Medical Officer of Aligos, added, “ALG-000184 has demonstrated potent inhibition of HBV DNA and RNA levels in preclinical studies. This observation, coupled with the drug’s clinical profile to date, led us to initiate dosing with ALG-000184 in CHB patients to assess its ability to suppress HBV DNA and RNA levels. We expect to begin reporting safety, pharmacokinetic, and antiviral activity data for ALG-000184 from the initial patient cohorts of this study in the second half of 2021.”

Professor Ed Gane, MB ChB, Principal Investigator for the ALG-000184-201 study, added, “I believe that combinations of drugs that collectively reduce S-antigen and HBV DNA/RNA levels have the potential to achieve significantly higher rates of functional cure than the current standard of care. By advancing their STOPS molecule drug candidate, ALG-010133, and now their CAM drug candidate, ALG-000184, separately into CHB patients, Aligos is laying the groundwork for future combination studies in CHB, where we can test this important hypothesis.”

ALG-000184-201 (NCT04536337) is a multi-part umbrella trial that is evaluating the safety, pharmacokinetics (PK) and antiviral activity of up to 28 daily oral doses of ALG-000184 in treatment-naïve CHB patients as well as CHB patients not currently being treated. The study also previously evaluated the safety and PK of up to 7 oral daily doses of ALG-000184 in 48 healthy volunteers and preliminary data indicate that ALG-000184 has a good safety and PK profile and can achieve drug levels expected to confer antiviral activity.

Aligos’ CAM program represents one of several in the company’s CHB portfolio that target different clinically validated mechanisms of action in the hepatitis B virus life cycle. The portfolio also includes
S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPSTM) molecules, antisense oligonucleotide (ASO), and small interfering RNA (siRNA) drug candidates. The properties of these candidates indicate that their use in combination could yield potentially best-in-class treatment regimens that may achieve higher rates of functional cure than current standard of care. For each of these drug candidates, Aligos plans to initially establish proof of concept as monotherapy in Phase 1 umbrella trials before evaluating them in combination in subsequent trials.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Aligos’ expectation of reporting safety, pharmacokinetic, and antiviral activity data for ALG-000184 from the initial patient cohorts of the study in the second half of 2021; the achievement of higher rates of functional cure than the current standard of care through the combinations of drugs that collectively reduce S-antigen and HBV DNA/RNA levels; plans of future combination studies in CHB by advancing Aligos’ STOPS molecule drug candidate, ALG-010133, and now its CAM drug candidate, ALG-000184, separately into CHB patients; the expectation that the drug levels achieved at doses evaluated in healthy volunteers will result in antiviral activity and thus supporting further evaluation of ALG-000184 in CHB patients; and Aligos’ plans to initially establish proof of concept as monotherapy in Phase 1 umbrella trials for each of its CAM, STOPS, ASO and siRNA candidates before evaluating them in combination in subsequent trials. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 23, 2021 and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]